Feb 26, 2016

Posted by in Stock Reports | 0 Comments

Analyst coverage launches on these three stocks: Biogen Inc (NASDAQ:BIIB), Gilead Sciences Inc (NASDAQ:GILD), Celgene Corporation (NASDAQ:CELG)

Analyst coverage launches on these three stocks: Biogen Inc (NASDAQ:BIIB), Gilead Sciences Inc (NASDAQ:GILD), Celgene Corporation (NASDAQ:CELG)

Wall Street analysts’ recommendations can move markets. Stock analysts sift through company reports and filings, talk to company management, probe customers and competitors and basically do whatever they can to find out if a company is healthy and growing or sick and shrinking. Because this is incredibly demanding work, stock analysts typically only monitor one or two companies at a time. Analysts also issue projected price targets of where they believe the stock price is going to be 12 months down the road.

The reputation and credibility of a company and the research firm depends on the efforts they make to inform investors. A company does not want to be tarnished by being associated with disreputable research. Similarly, a research firm will only want to analyze companies that have strong fundamentals and long-term investment potential.

Citigroup announced it was initiating coverage of Biogen Inc (NASDAQ:BIIB) in a research note on Thursday. The analysts assigned a Buy rating to the stock with a price target of $345. The average analysts that follow this company have a ‘Strong Buy’ rating on this stock, according to Zacks Investment Research. Ten maintain strong buy rating, 2 set the stock as buy, Zero give underperform rating and Zero suggests selling.

Citigroup analysts issued their verdict on Gilead Sciences Inc (NASDAQ:GILD) recently. The rating firm gave a Buy rating to this stock with a price target of $110 in a research note on Thursday. The stock has a consensus Strong Buy rating, according to Zacks Investment Research. No analyst has rated the stock with a sell rating, 5 have assigned a hold rating, 2 say it’s a buy, and 10 have assigned a strong buy rating to the company.

In a research note on Thursday, analysts at Citigroup assigned a Buy rating to Celgene Corporation (NASDAQ:CELG) and set the price target of $130. It has earned a consensus Strong Buy rating, according to Zacks Investment Research. No analyst has rated the stock with a sell rating, 3 have assigned a hold rating, 1 says it’s a buy and 12 have assigned a strong buy rating to the company.

 

Comments are closed.